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Abstract
Background: We aimed to compare rates of virologic response and CD4 changes after combination antiretroviral (cART)
initiation in individuals infected with B and specific non-B HIV subtypes.
Methods: Using CASCADE data we analyzed HIV-RNA and CD4 counts for persons infected $1996, $15 years of age. We
used survival and longitudinal modeling to estimate probabilities of virologic response (confirmed HIV-RNA,500 c/ml), and
failure (HIV-RNA.500 c/ml at 6 months or $1000 c/ml following response) and CD4 increase after cART initiation.
Results: 2003 (1706 B, 142 CRF02_AG, 55 A, 53 C, 47 CRF01_AE) seroconverters were included in analysis. There was no
evidence of subtype effect overall for response or failure (p = 0.075 and 0.317, respectively) although there was a suggestion
that those infected with subtypes CRF01_AE and A responded sooner than those with subtype B infection [HR (95% CI):1.37
(1.01–1.86) and 1.29 (0.96–1.72), respectively]. Rates of CD4 increase were similar in all subtypes except subtype A, which
tended to have lower initial, but faster long-term, increases.
Conclusions: Virologic and immunologic response to cART was similar across all studied subtypes but statistical power was
limited by the rarity of some non-B subtypes. Current antiretroviral agents seem to have similar efficacy in subtype B and
most widely encountered non-B infections in high-income countries.
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Introduction
HIV-1 is characterized by its high genetic diversity and is
classified into 4 groups, M, N, O and P [1] with group M
dominating the epidemic worldwide. Group M is further classified
into 9 subtypes (A-D, F-H, and K) and an increasing number of
inter-subtype circulating recombinant forms (CRFs) and unique
recombinant forms (URFs). Globally, subtype C accounts for
almost 48% of infections and dominates the epidemic in Southern
Africa, India and China, followed by subtype A (<27%) which
dominates in Eastern Africa, Eastern Europe and Central Asia.
Subtype B accounts for about 12% of HIV infections worldwide
[2,3] and, although it dominates in high-income countries, the
prevalence of non-B subtypes has increased in those countries in
recent years, mainly due to mixing of populations [2,4].
Antiretroviral drugs have been developed mainly using subtype
B as the reference virus and in vitro studies have suggested that
subtype may affect susceptibility to certain drugs [2,5–7]. Given
the globally increasing HIV-1 genetic heterogeneity and wider
availability of combination antiretroviral therapy (cART), it is
important to assess whether it is equally active against all subtypes
and CRFs. Although parallel epidemics of different subtypes are
now commonly observed, they tend to be restricted to specific
ethnic or risk groups making comparisons across subtypes difficult.
Most of the previous studies assessing virological and immuno-
logical response to cART by HIV-1 subtype had the serious
limitation of grouping all non-B subtypes together due to small
numbers [8–14]. The few studies that examined the effect of single
subtypes were restricted to specific subtypes depending on the
geographic region from which the study population was derived
[15–17]. Taking advantage of CASCADE, a large international
collaboration of seroconverter cohorts, we aimed to investigate the
effect of specific HIV-1 subtypes on immunological and virological
response to cART in persons living in high-income countries.
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Methods
Ethics statement
All collaborating cohorts received approval from their respective
or national ethics review boards. Ethics approval for CASCADE
collaborating cohorts has been granted by the following commit-
tees: Austrian HIV Cohort Study: Ethik-Kommission der
Medizinischen Universita¨t Wien, Medizinische Universita¨t Graz
– Ethikkommission, Ethikkommission der Medizinischen Univer-
sita¨t Innsbruck, Ethikkommission des Landes Obero¨sterreich,
Ethikkommission fu¨r das Bundesland Salzburg; PHAEDRA
cohort: St Vincent’s Hospital, Human Research Ethics Commit-
tee; Southern Alberta Clinic Cohort: Conjoint Health Research
Ethics Board of the Faculties of Medicine, Nursing and
Kinesiology, University of Calgary; Aquitaine Cohort: Commis-
sion Nationale de l’Informatique et des Liberte´s; French Hospital
Database: Commission nationale de l’informatique et des liberte´s
CNIL; French PRIMO Cohort: Comite Consultatif de Protection
des Personnes dans la Recherche´ Biomedicale; SEROCO Cohort:
Commission Nationale de l’Informatique et des Liberte´s (CNIL);
German HIV-1 Seroconverter Study: Charite´, University Medi-
cine Berlin; AMACS: Bioethics & Deontology Committee of
Athens University Medical School and the National Organization
of Medicines; Greek Haemophilia Cohort: Bioethics & Deontol-
ogy Committee of Athens University Medical School and the
National Organization of Medicines; ICoNA cohort: San Paolo
Hospital Ethic Committee; Italian Seroconversion Study: Comi-
tato etico dell’Istituto Superiore di Sanita`; Amsterdam Cohort
Studies in Homosexual Men and IDUs: Academic Medical
Centre, University of Amsterdam; Oslo and Ulleval Hospital
Cohorts: Regional komite for medisinsk forskningsetikk – Øst-
Norge (REK 1); Badalona IDU Hospital Cohort: Comite´ E´tico de
Investigacio´n Clı´nica del Hospital Universitari Germans Trias i
Pujol; CoRIS-scv: Comite´ E´tico de Investigacio´n Clı´nica de La
Rioja; Madrid Cohort: Ethics Committee of Universidad Miguel
Hernandez de Elche; Valencia IDU Cohort: Comite´ Etico de
Investigacio´n Clı´nica del Hospital Dr. Peset-Valencia; Swiss HIV
Cohort Study: Kantonale Ethikkommission, spezialisierte Unter-
Table 1. Demographic and clinical characteristics of the study population at cART initiation.
HIV-1 subtype
A
(N=55)
B
(N=1,706)
C
(N=53)
CRF01_AE
(N=47)
CRF02_AG
(N=142)
Overall
(N=2,003)
p-value
p-value
Risk group & Gender ,0.001*
MSM1 12 (21.8) 1342 (78.7) 12 (22.6) 11 (23.4) 52 (36.6) 1429 (71.3)
Male IDU2 1 (1.8) 47 (2.8) 2 (3.8) 1 (2.1) 0 (0.0) 51 (2.5)
Female IDU 0 (0.0) 27 (1.6) 1 (1.9) 0 (0.0) 0 (0.0) 28 (1.4)
Male MSW3 18 (32.7) 119 (7.0) 15 (28.3) 26 (55.3) 29 (20.4) 207 (10.3)
Female MSW 22 (40.0) 101 (5.9) 19 (35.8) 9 (19.1) 54 (38.0) 205 (10.2)
Other-Unknown 2 (3.6) 70 (4.1) 4 (7.5) 0 (0.0) 7 (4.9) 83 (4.1)
Ethnic/racial group ,0.001*
White 41 (74.5) 1281 (75.1) 41 (77.4) 38 (80.9) 76 (53.5) 1477 (73.7)
Black 7 (12.7) 45 (2.6) 8 (15.1) 2 (4.3) 33 (23.2) 95 (4.7)
Other 1 (1.8) 53 (3.1) 1 (1.9) 4 (8.5) 3 (2.1) 62 (3.1)
Unknown 6 (10.9) 327 (19.2) 3 (5.7) 3 (6.4) 30 (21.1) 369 (18.4)
Acute infection4 25 (45.5) 752 (44.1) 17 (32.1) 19 (40.4) 106 (74.6) 919 (45.9) ,0.001*
AIDS before cART 1 (1.8) 76 (4.5) 3 (5.7) 2 (4.3) 3 (2.1) 85 (4.2) 0.586*
ART naı¨ve 52 (94.5) 1655 (97.0) 50 (94.3) 47 (100.0) 141 (99.3) 1945 (97.1) 0.158*
cART based on 0.027*
Unboosted PI 6 (10.9) 302 (17.7) 6 (11.3) 4 (8.5) 17 (12.0) 335 (16.7)
NNRTI 21 (38.2) 628 (36.8) 28 (52.8) 22 (46.8) 42 (29.6) 741 (37.0)
Boosted PI 26 (47.3) 703 (41.2) 18 (34.0) 21 (44.7) 77 (54.2) 845 (42.2)
3 class/Other 2 (3.6) 73 (4.3) 1 (1.9) 0 (0.0) 6 (4.2) 82 (4.1)
CD4 cell count/mm3 329 330 290 309 338 330 0.207**
(cells/ml) (264, 580) (236, 470) (213, 393) (201, 463) (243, 438) (235, 468)
Plasma HIV-RNA
(log10 c/ml)
4.8 (0.9) 5.0 (0.8) 5.0 (0.9) 4.9 (0.8) 5.0 (0.9) 5.0 (0.8) 0.143**
Age (years) 40.6 (13.5) 37.2 (9.3) 38.8 (14.0) 44.1 (11.1) 37.3 (11.0) 37.5 (9.8) ,0.001**
Calendar year 2004 2004 2005 2006 2006 2005 ,0.001**
at cART initiation (02, 08) (01, 07) (02, 07) (03, 08) (03, 08) (01, 08)
SC to cART (months) 17 (1, 37) 13 (2, 33) 17 (6, 33) 26 (4, 44) 6 (1, 26) 13 (1, 33) 0.001**
Numbers in upper panel are N(%) and in lower panel Mean (SD) or Median (IQR).
1: men having sex with men; 2: intravenous drug users; 3: sex between men and women; 4: as indicated by a short (,30 days) HIV test interval.
*:Chi-square test; ** Kruskal-Wallis test.
doi:10.1371/journal.pone.0071174.t001
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kommission Innere Medizin, Ethikkommission beider Basel,
Kantonale Ethikkommission Bern, Comite´ de´partemental d’e´thi-
que de me´decine et me´decine communautaire, Commission
d’e´thique de la recherche clinique, Universite´ de Lausanne,
Comitato etico cantonale, Ethikkommission des Kantons St.Gal-
len; UK Register of HIV Seroconverters: South Birmigham REC;
Early Infection Cohorts: Kenya Medical Research Institute,
Kenyatta National Hospital, Uganda Virus Research Institute
Science and Ethics Committee, Uganda National Council for
Science and Technology, Uganda Virus Research Institute
Science and Ethics Committee, Uganda National Council for
Science and Technology, University of Zambia Research Ethics
Committee, Emory IRB, National Ethics Committee of Rwanda,
University of Cape Town Research Ethics Committee, University
of Kwazulu Natal Nelson R Mandela School of Medicine; Genital
Shedding Study Cohort: University Hospitals of Cleveland, IRB
for Human Investigation (CWRU), AIDS Research Committee
(ARC), STD/AIDS Control Programme, Uganda Ministry of
Health, Committee on Human Research (CHR), Office of
Research Administration (UCSF), Biomedical Research & Train-
ing Institute (BRTI) – Zimbabwe, Institutional Review Office,
Fred Hutchinson Cancer Research Center, Medical Research
Council of Zimbabwe (MRCZ). Written informed consent was
obtained from all participants.
Study population
We used data from CASCADE (Concerted Action of Serocon-
version to AIDS and Death in Europe), a collaboration of 28
cohorts of individuals with well-estimated dates of HIV serocon-
version (seroconverters) [18]. Seroconversion dates were estimated
by various methods, most frequently as the midpoint between the
last documented negative and first positive HIV antibody test
dates with an interval of less than 3 years between tests (84.6%).
The remainder were estimated through the availability of
laboratory evidence of acute seroconversion (PCR positivity in
the absence of HIV antibodies or antigen positivity with fewer
than four bands on Western blot), or as the date of seroconversion
illness with both an earlier documented negative and a later
positive HIV test not more than 3 years apart.
Individuals followed-up in two African cohorts in CASCADE
were excluded as treatment guidelines applied to these populations
differ from those in high-income countries. We also excluded
individuals who seroconverted ,1996 when cART became
available. Eligible individuals were .15 years at seroconversion,
started a stable cART regimen (i.e. at least 60 days) and had both
CD4 and HIV-RNA measurements available at baseline (i.e.
within the last 6 months prior to cART initiation) and while on
their first cART regimen. As the main focus of this analyses was on
response to cART, individuals with HIV-RNA,500 copies/ml at
cART initiation were also excluded.
Follow-up time was censored at the first major treatment
modification (i.e. change of cornerstone drug or simultaneous
change of at least two backbone drugs) or at a treatment
interruption lasting .14 days.
cART was defined as a protease inhibitor (PI)-based, non-
nucleoside reverse transcriptase inhibitor (NNRTI), or fusion
inhibitor-based regimen, in combination with at least two
nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs),
or a triple NRTI regimen including abacavir or tenofovir.
Virologic response was defined as time to the first of two
successive HIV-RNA ,500 copies/ml. Virologic failure was time
to the first of two HIV-RNA $500 copies/ml, to the first
(unconfirmed) measurement of$1000 HIV-RNA copies/ml, or to
6 months after cART for those not responding by that time.
Laboratory methods
Sequencing was performed by investigators in the country of
origin, using various genotypic resistance assays. HIV-1 subtype
was derived from nucleotide sequence data spanning the entire
protease gene and at least codons 41–236 of reverse transcriptase
using the Rega algorithm [19]. HIV-RNA values were also
determined locally. We defined response as HIV-RNA to ,500
copies/ml as this was the limit of detection for the least sensitive
assay used.
Statistical analysis
Cumulative incidence of response or failure, in the presence of
the competing event of switching to a new cART regimen, was
estimated through the non-parametric Aalen-Johansen estimator
[20]. The cause-specific hazards of response and failure were
analysed using the Cox proportional hazards model [21]. We also
examined CD4 count change following cART based on a piece-
wise linear mixed model, with change in slope 3 months after
initiation. Multivariable models were adjusted for gender, risk
group [men having sex with men (MSM), sex between men and
Figure 1. Cumulative incidence of initial virologic response (A)
and virologic failure (B) by HIV-1 subtype. Numbers below each
subfigure indicate numbers of individuals ‘‘at risk’’ (i.e. subjects not
responded (A) or failed (B) and under follow-up).
doi:10.1371/journal.pone.0071174.g001
Response to cART by HIV-1 Subtype
PLOS ONE | www.plosone.org 3 July 2013 | Volume 8 | Issue 7 | e71174
women (MSW), injecting drug users (IDU), other/unknown], age
at cART initiation, pre-cART antiretroviral experience (naive,
experienced), time from seroconversion to cART initiation (,6, 6–
48, $48 months indicating early, medium and late treated), initial
cART (unboosted PI, boosted PI, NNRTIs, other), and log10 HIV-
RNA levels at cART initiation (baseline).
Monte Carlo based power calculations (500 replications/
outcome) were used to determine the minimum effect sizes
required to achieve a power of at least 0.80 at an alpha level of
0.05 given the sample size per subtype, follow-up time (simulated
by an exponential distribution of censoring times), CD4 cell count
distribution over time (simulated by a random effects piecewise
linear model) and rates of virologic response/failure (simulated by
Weibull and Gompertz distributions, respectively) in our study.
Parameters values for the simulation were based on real data
analyses. These calculations were performed for all major analyses
and for comparisons of subtype B group with the smallest and
largest non-B subtype groups.
A set of sensitivity analyses were undertaken. Firstly, to allow for
the potentially confounding effect of ethnicity, final models were i)
further adjusted for ethnicity (white, black, other, and unknown) or
ii) restricted to white only. Secondly, as individuals treated during
primary HIV-1 infection may have different responses compared
to those treated during chronic infection, final analyses were
repeated excluding those who initiated cART within 1 year of
seroconversion and with CD4 counts .350 cells/ml. Thirdly,
analyses were restricted to those who started cART after year 2000
when boosted PIs became widely available. Fourthly, IDUs were
excluded from analyses as response in this group is known to be
lower compared to other risk groups (mainly due to poor
adherence). Finally, to minimize selection bias, analyses were
restricted to those cohorts with .50% of their participants
subtyped.
Results
Study population characteristics
The CASCADE database, updated in September 2011 within
EuroCoord (www.EuroCoord.net), included data from 25,629
individuals of whom 15,175 initiated cART during follow-up. Of
these, 8,492 were excluded from all analyses as follows: 156 from
the 2 African cohorts, 5,672 who seroconverted ,1996, 1 aged
,15 years, 1,529 who were on their first cART regimen for
Table 2. Factors associated with cause-specific hazard of initial virologic response and virologic failure after cART initiation.
Virologic response Virologic failure
Factor HR 95% C.I. p-value* HR 95% C.I. p-value*
HIV subtype 0.075 0.317
A 1.29 (0.96, 1.72) 0.76 (0.33, 1.74)
B 1 1
C 1.20 (0.90, 1.60) 0.71 (0.35, 1.46)
CRF01_AE 1.37 (1.01, 1.86) 0.33 (0.08, 1.33)
CRF02_AG 1.15 (0.96, 1.39) 0.72 (0.45, 1.17)
Log10 HIV-RNA at cART initiation ,0.001 0.029
per 1 log10 c/ml 0.70 (0.66, 0.75) 1.16 (1.01, 1.32)
Risk group ,0.001 0.020
MSM1 1 1
IDU2 0.64 (0.49, 0.83) 1.84 (1.25, 2.71)
MSW3 0.81 (0.71, 0.92) 1.10 (0.82, 1.47)
Other-Unknown 0.95 (0.76, 1.20) 1.19 (0.71, 1.97)
Pre-cART ART experience ,0.001 ,0.001
Naı¨ve 1 1
Experienced 0.58 (0.43, 0.79) 2.39 (1.55, 3.68)
Time from seroconversion to cART initiation ,0.001
,6 months 1
[6, 48 months) 0.71 (0.64, 0.79)
$48 months 1.18 (1.02, 1.37)
cART based on ,0.001 ,0.001
Unboosted PI 1 1
NNRTI 1.55 (1.34, 1.80) 0.45 (0.35, 0.59)
Boosted PI 1.42 (1.23, 1.64) 0.36 (0.27, 0.48)
3 class/Other 0.88 (0.68, 1.15) 1.15 (0.79, 1.68)
Age at cART initiation 0.001
per 10 years 0.82 (0.72, 0.92)
1: men having sex with men; 2: injecting drug users; 3: sex between men and women. Each factor is adjusted for all other factors in Table.
*global Wald-type tests based on the fit of the corresponding models.
doi:10.1371/journal.pone.0071174.t002
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,60 days, and 1,134 as CD4 cell count and/or HIV-RNA
measurements at cART initiation or while on cART were not
available. Of 6,683 eligible individuals, HIV-1 subtype was known
for 2,152 (32.2%). Individuals with known subtypes were, on
average, more likely to be white, of non sub-Saharan African
origin and infected through sex between men. They also had
higher viraemia at cART initiation (mean viral load 4.9 vs. 4.5
log10 copies/ml; p,0.001); shorter delays between seroconversion
and cohort enrolment (median 1 vs. 7 months; p,0.001) and
initiated cART at slightly higher CD4 counts (median 330 vs. 316
cells/ml; p,0.001).
Of the 2,152 with known HIV-1 subtype, 54 had HIV-RNA
,500 copies/ml at cART initiation and were, therefore, excluded
from further analyses. Of the remaining 2,098, the predominant
subtypes were B (n = 1706, 81.3%), followed by CRF02_AG
(n = 142, 6.8%), A (n = 55, 2.6%), C (n = 53, 2.5%), CRF01_AE
(n = 47, 2.2%), other recombinants (n = 47, [2.2%]: 34 with
various CRFs and 13 with URFs), and various other subtypes
(n = 48 [2.3%]: 14 D, 12 F, 21 G and 1 J). As our main aim was to
investigate the effect of each single subtype, we excluded subtypes
infecting fewer than 30 individuals. Our analyses were thus
restricted to 2003 individuals, the demographic and clinical
characteristics of whom are shown in Table 1 according to HIV-1
subtype. Individuals with non-B subtypes were more likely to be
black, infected through MSW, slightly older, and more likely to
initiate cART in more recent calendar periods (and hence less
likely to initiate an unboosted PI-based regimen) compared to
those with subtype B. Viraemia and CD4 count at cART initiation
were similar across all groups. Individuals with CRF02_AG
started cART significantly sooner after seroconversion compared
to those infected by other subtypes.
Of 607 individuals initiating cART within one year of
seroconversion and with CD4 counts .350 cells/ml, 338 (55.7%)
were from the PRIMO cohort in France, reflecting the policy in
this country during the 1996–2004 period to systematically treat
individuals presenting during primary HIV-1 infection. However,
the rate of ‘‘early’’ treated subjects did not differ significantly by
HIV-1 subtype (p = 0.479). Notably, the majority of those infected
with CRF02_AG (93/142, 65.5%) were also from the PRIMO
cohort, which may explain the shorter time intervals between
seroconversion and cART initiation observed for that subtype.
As the analysis of virological response may be sensitive to the
time of HIV-RNA measurements, we compared median follow-up
time, number of HIV-RNA measurements and time interval
between consecutive measurements across subtypes and found no
significant differences (p.0.39 in all cases).
Virological Response
Of 2003, 1,847 responded virologically with cumulative
incidence (95% CI) of 87.0% (85.4, 88.4) at 6 months after cART
initiation, which did not differ significantly by HIV-1 subtype
(p = 0.097) (Figure 1A).
Figure 2. Observed (A) and predicted (B) CD4 cell count by HIV-
1 subtype. A: Median profiles (numbers on top indicate individuals
contributing measurements at each time point), B: based on a
piecewise linear mixed model (Non acute infection, without AIDS at
cART initiation, boosted PI cART, SC to cART.4 years, previously naı¨ve,
5 log10 c/ml initial viral load, men having sex with men, 30 years old at
cART initiation).
doi:10.1371/journal.pone.0071174.g002
Table 3. Estimated median (95% CI) CD4 cell count by HIV-1 subtype and time since cART initiation.
Time
HIV subtype cART initiation 3 months 6 months 1 year 2 years
A 307 (261, 357) 440 (380, 505) 467 (406, 532) 522 (458, 590) 642 (561, 728)
B 268 (250, 287) 449 (422, 477) 467 (439, 495) 504 (476, 533) 582 (548, 617)
C 255 (212, 301) 438 (378, 503) 455 (395, 519) 490 (428, 555) 563 (490, 640)
CRF01_AE 271 (225, 321) 416 (355, 483) 436 (374, 502) 476 (412, 545) 563 (484, 648)
CRF02_AG 236 (206, 268) 410 (367, 455) 428 (385, 473) 465 (421, 512) 545 (491, 601)
(Non acute infection, without AIDS at cART initiation, boosted PI cART, seroconversion to cART .4 years, previously naı¨ve, $5 log10 c/ml initial viral load, men having
sex with men, 30 years old at cART initiation).
doi:10.1371/journal.pone.0071174.t003
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In an unadjusted analysis, given the low numbers with non-B
subtypes and comparing the subtype B group to the smallest (i.e.
CRF01_AE) and the largest (i.e. CRF02_AG) non-B subtype
groups, we estimated that we would have 80% power, at an alpha
level of 0.05, to detect hazard ratios of 1.53 and 1.27, respectively.
Pairwise comparisons through an unadjusted cause-specific
proportional hazards model, however, indicated that, compared to
those with subtype B, individuals with CRF01_AE and A
experienced higher rates of response (HR = 1.37; 95% CI: 1.02–
1.84 and 1.28; 0.97–1.70, respectively). Adjusting for factors
mentioned in the methods section yielded similar results (Table 2).
Rates of response were also higher for individuals with low
baseline viraemia, MSM (compared to other groups), those naı¨ve
at cART initiation, those initiating cART,6 or$48 months after
seroconverion and those on boosted PI or NNRTI-based
regimens.
Excluding individuals who initiated cART during the first year
of seroconversion with CD4 .350 cells/ml yielded similar results
although the difference between A and B was attenuated. Similar
results were obtained when IDUs were excluded from the analysis.
Restricting analyses to individuals who started cART after year
2000, those belonging to cohorts with .50% of their participants
subtyped, and only whites or adjusting also for ethnicity, yielded
results compatible with those of the main analysis, although
hazard ratios when comparing individuals with non-B subtypes to
those with subtype B were slightly attenuated and non-significant
(data not shown), most likely due to reduced sample size.
Virologic failure
After excluding 119 individuals with less than 180 days of
available follow up, 158 (8.4%) of the remaining 1,884 failed
having initially responded, and 208 (11.0%) had not responded by
6 months. The overall mean (95% CI) estimated cumulative
incidence of failure 24 and 48 months after cART initiation was
20.6% (18.7, 22.7) and 23.1% (20.9, 25.3), respectively. There was
relatively weak evidence (p = 0.059) to suggest that individuals with
non-B subtypes were more likely to experience lower rates of
failure (Figure 1B).
Comparing to subtype B, we estimated that the minimum effect
sizes (i.e. hazard ratios) that could be detected with 80% power, at
an alpha level of 0.05, were 0.42 and 0.59 for subtypes CRF01_AE
and CRF02_AG, respectively.
The most pronounced and significant difference was between
individuals infected with CRF01_AE and B subtype (unadjusted
HR = 0.23, 95% CI: 0.06–0.92; p = 0.039). In multivariable
analysis though, differences between subtypes were attenuated
with no evidence of a difference in risk of failure rate by subtype
(Table 2; overall p = 0.317). Results from the same model
indicated that individuals infected through IDU, at younger ages,
pre-treated, with higher baseline HIV-1 RNA and with an
unboosted PI-based cART, were independently associated with
higher probabilities of virological failure.
Sensitivity analyses similar to those performed for the virological
response outcome, yielded comparable results with non-B subtypes
having mainly protective (i.e. hazard ratios,1) but non-significant
effects.
Immunological response
Increases in CD4 cell count after cART initiation were biphasic
with steep initial (first 3 months) increase followed by milder long-
term (after 3 months) increase. Median CD4 cell count profiles by
HIV-1 subtype and time since cART initiation are shown in
Figure 2A. However, caution is required when interpreting such
figures due to their cross-sectional nature as the number of
individuals contributing measurements at each time point is not
constant and is influenced by missed visits and other censoring
mechanisms (mainly switching to a new cART regimen).
Results from an unadjusted piecewise linear mixed model with a
knot at 3 months after cART initiation showed that individuals
with subtype A experienced slower (p = 0.006) initial and faster
(p = 0.014) long-term rates of CD4 increases compared to
individuals infected with subtype B. No such differences were
detected for any other subtype. After adjusting for all previously
mentioned covariates, individuals infected with subtype A still
experienced slower initial CD4 increase (p = 0.007) and faster
long-term CD4 cell increase (p = 0.012). Estimated initial average
increases ranged from 160 to 200 CD4 cells/ml for individuals
infected with subtypes A and C, respectively. The estimated
increase at two years ranged from 292 to 335 CD4 cells/ml for
individuals infected with subtypes CRF01_AE and A, respectively.
Estimated median (95% CI) CD4 cell counts at various time points
and longitudinal trends by HIV-1 subtype for a typical subgroup
are shown in Table 3 and Figure 2B, respectively.
Based on our power calculations, differences in CD4 count
gains at 1 year after cART initiation, comparing subtype B group
to the smallest (i.e. CRF01_AE) and largest (i.e CRF02_AG) non-
B subtype groups of 80 and 50 cells/mL respectively, could be
detected with 80% power at an alpha level of 0.05.
Performing the same procedures of sensitivity analyses as
mentioned earlier and adjusting for baseline CD4 cell count,
yielded results consistent with those of the main analysis.
Discussion
Using data from CASCADE, a large collaborative study, we
had sufficiently large numbers to compare virologic and immu-
nologic response to cART among individuals infected with
subtypes A, B, C, CRF01_AE and CRF02_AG. Overall, we
found no clinically important differences between different HIV-1
subtypes and virological and immunological response to cART,
and virological failure. However, there were some indications that
those infected with subtype CRF01_AE and, to a lesser extent,
with subtype A, responded sooner compared to subtype B. The
difference between CRF01_AE and B subtype persisted in almost
all sensitivity analyses. Although all non-B subtypes tended to have
lower rates of virological failure compared to subtype B, when
comparing each specific non-B subtype to subtype B no significant
differences were found. This is an important finding given that
cART drugs were generally developed based on efficacy to
subtype B whereas the vast majority of the global HIV epidemic
comprises non-B subtypes.
Our findings of shorter time to suppression for subtype A,
compared to B, and a lack of any difference in failure rates by
subtype support those of others [15]. Easterbrook et al [16],
reported no significant differences in virological response and
subsequent rebound for subtypes B, A, C and CRF02_AG. In that
study, they also reported higher rates of virological rebound for
subtype D compared with subtype B. In our study we did not have
sufficient number of D infections (n = 14) to confirm this finding.
On the other hand, recently published data from the Swiss HIV
Cohort study (SHCS) [22] have shown that, restricting analyses to
whites only, individuals infected with non-B subtypes had a lower
risk of virologic failure than those infected with B subtype. In
particular, subtypes A and CRF02_AG had improved outcome. In
our study, when comparing jointly all non-B subtypes to subtype B
the point estimate was the same as the one reported from the
SHCS cohort (adjusted HR for non-B/B = 0.68) and statistically
significant (p = 0.048). When single subtypes where considered no
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significant inter-subtype differences were found. This could be due
to reduced power, even though the number of individuals infected
with CRF02_AG subtype was comparable in the two studies (142
in CASCADE vs. 128 in the Swiss cohort).
Evaluation of virological response may be sensitive to the timing
of HIV-RNA measurements. Therefore, differences in HIV-RNA
measurements timing by HIV-1 subtype may influence results
regarding virologic response. However, in our study we did not
find any difference in median follow-up time; number of HIV-
RNA measurements or the time interval between consecutive
measurements by HIV-1 subtype. Higher baseline viremia is
associated with poorer response to cART initiation. In our study
baseline viremia was similar across HIV-1 subtypes, which was, in
any case, adjusted for in all our analyses.
Most previous studies have not found any significant difference
between HIV-1 subtype and rates of CD4 increases after cART
initiation [8–10,13,15,17,23]. In one, relatively small, study [14],
CD4 increases at 24 months after cART initiation were lower for
individuals with non-B subtypes, but this difference was mainly
due to the lower baseline CD4 counts for those harboring subtype
A. In a larger study [15] lower baseline CD4 in individuals
infected with non-B subtypes, compared to those with B subtype,
was reported. Rates of CD4 count recovery were similar overall
but, due to initial differences, the CD4 count gap between non-B
and B infections persisted throughout therapy. In our study, after
adjusting for several factors including time from SC to cART
initiation, those infected with non-B subtypes, except for subtype
A, tended to initiate cART at slightly lower CD4 counts,
compared with those infected with B subtype, although the
difference was significant only for those infected with CRF02_AG.
Those infected with subtype A had lower initial but also faster
long-term CD4 increases than those infected with subtype B.
When ethnicity was also considered, with or without HIV-1
subtype adjustment, blacks tended to have lower CD4 counts at
cART initiation, but rates of CD4 recovery did not vary
significantly by ethnicity.
It is known that unboosted PIs have lower efficacy than boosted
PI or NNRTI-based regimens. In our study, individuals infected
with subtype B, were more likely to initiate unboosted PI-based
regimens compared to those with non-B subtypes. This was mainly
because they started therapy in earlier calendar periods before the
prevalence of non-B subtypes increased in Western cohorts [24–
29]. As we have controlled for cART regimen, this difference is
unlikely to have affected our results. Additionally, a sensitivity
analysis restricting data to those who started cART after year 2000
was carried out and results were similar to those of the main
analyses in all cases.
Jensen-Fangel et al [23] comparing whites with non-whites in a
Danish cohort of HIV-1 seropositives under cART found no
significant differences between them in virological response,
clinical progression or immunologic response rates. Frater et al
[9] found no significant differences in virological response between
those infected with B and non-B subtypes (mainly infected with A,
C or D). Comparing European with African cohorts, however,
while there was no difference in initial (short term) virological
response rates, long-term virological response tended to be poorer
in African cohorts, indicating that ethnicity, rather than HIV-1
subtype, may be a more important determinant of long-term
virologic response to cART [9]. As expected, HIV-1 subtype was
strongly associated with ethnicity and risk group in our study. We
used a set for sensitivity analyses to allow for potential confounding
effects of these factors and, in all cases, results were compatible
with those of the main analyses. Although residual confounding
can never be ruled out in observational studies, we believe that the
lack of any significant and/or clinically important association
between HIV-1 subtype and long-term virological response or
immune reconstitution rates is unlikely to be attributed to residual
confounding. These results are supported by the recent findings
from the SHCS that fully controlled for ethnicity [22].
Low adherence is an important determinant of poor virologic
response. Adherence data are not collected in CASCADE. Some
studies have suggested that adherence levels are lower in
immigrants/minorities than in indigenous populations, with this
difference being mainly attributed to differences in cultural and
socioeconomic factors [30–32]. If adherence levels differed by
HIV-1 subtype, given that non-B subtypes are more common in
non-whites, controlling for adherence would have resulted in even
lower rates of virological failure for those infected with non-B
subtypes. In the UK CHIC study [15], for example, it was found
that those infected with subtype C had increased risk of virologic
rebound relative to those infected with subtype B. However, this
difference was not observed when virologic rebound, which was
likely to be related to non-adherence was excluded.
Although this is one of the largest studies addressing the
question of virologic and immunologic response to cART, the
numbers of some specific HIV-1 subtypes were relatively low
leading to reduced power to detect potential inter-subtype
differences. Additionally, we were not able to study the whole
spectrum of HIV-1 subtypes due to small numbers. Even larger
cohort collaborations are needed to fully address this question
across all HIV-1 subtypes. Despite these limitations, our study is
one of the few studies that had large enough numbers to compare
responses to cART initiation in patients infected with subtypes B,
A, C, CRF01_AE and CRF02_AG followed in high-income
countries with similar access to care. Although our results are
subject to the limitation posed by the observational nature of the
study, we have shown: similar or even higher probabilities of
virologic response to cART among individuals infected with non-B
subtypes compared to those with B subtype, equally low rates of
virologic relapse across all subtype groups, and limited subtype
effects on immunologic response.
In conclusion, our results suggest that current antiretroviral
agents have, at least, similar efficacy when administered to persons
infected with non-B subtypes living in high-income countries. This
is important and reassuring information to HIV care givers and
their patients.
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